Jobs & Opportunities

Content is provided by our community of institutions, partners, researchers and journalists.

If you are a researcher or institution and would like to post a job announcement, please login to your Asia Research News account, and click ‘Add job’.

Research Associate- Prof Daniel Tenen’s Lab
Cancer Science Institute of Singapore | Open until filled

A research associate position is available immediately in Prof Daniel Tenen’s lab for a highly motivated Master or Ph.D. graduate with a background in molecular or cellular biology, biochemistry or other related fields who is interested in deciphering the functional roles of RNA editing enzymes in acute myeloid leukemia (AML). The successful candidate will help to design experiments, conduct experiments, analyse data, write papers and mentor students

Research Assistant – Dr Anand Jeyasekharan’s Lab
Cancer Science Institute of Singapore | Open until filled

A research assistant position is available immediately in Dr Anand Jeyasekharan’s lab at the Cancer Science Institute of Singapore, for a motivated and experienced scientist to drive a project investigating the determinants of immune activation after DNA damage in cancer.

Research Assistant- Prof Lee Soo Chin’s Lab
Cancer Science Institute of Singapore | Open until filled

Research Assistant (Telomere Biology) - Dr Dennis Kappei's Lab
Cancer Science Institute of Singapore | Open until filled

Research Fellow (Immunology & Cell Biology) - Prof. Lee Soo Chin's Lab
Cancer Science Institute of Singapore | Open until filled

Marketing communications - Asia Research News
Asia Research News | Open until filled

Asia Research News seeks a new marketing communications team member to advance the company’s brand visibility. This is a remote position. We welcome candidates from any location, especially from Asia.

Research Fellow - A/Prof. Edward Chow's Lab
Cancer Science Institute of Singapore | Open until filled

Optimizing Immunotherapy Combinations Against Hepatocellular Carcinoma The immunotherapy combination of atezolizumab–bevacizumab (AtezoBev) has been recently approved as first-line therapy in unresectable hepatocellular carcinoma (HCC). As such, combinatorial immunotherapy has proven to be a promising approach towards treating HCC. However, the vast majority of HCC patients still do not benefit from AtezoBev with only 33.2% overall response (NEJM 2020). We have developed a complex system analytics platform that can identify optimal drug combinations in drug-resistant cancers and primary patient samples (Sci Trans Med 2018, Blood Cancer J 2020, JECCR 2022). By applying this platform towards HCC patient-derived avatars, we seek to develop optimized immunotherapy combinations as well as understand the molecular mechanisms that drive sensitivity and resistance to these combinations compared to AtezoBev in specific HCC subtypes.

Research Associate - Prof. Yoshiaki Ito's Lab
Cancer Science Institute of Singapore | Open until filled

This position is an appointment to CSI MMA Core. We are looking for a meticulous and dedicated Research Pathologist to provide histological/morphological expertise to Researchers in CSI, N2CR and NCIS; and to assist researchers to optimise the use of tissues in their research design and approach. The Research Pathologist will assist in the selection of tissues/cases for analysis based upon researchers’ requests and will contribute to the daily running of our histology processing/ multiplex staining core service.

Research Fellow - Prof. Yoshiaki Ito's Lab
Cancer Science Institute of Singapore | Open until filled

Two postdoctoral positions are available immediately in Prof. Yoshiaki Ito’s lab. The successful candidates will undertake different aspects of the following on-going project. 1) Characterization of RUNX3 in stem cells and cancer development The RUNX family of developmental transcription factors, comprising RUNX1, 2 and 3, has been implicated in tumorigenesis. In particular, our work established RUNX3 as a regulator of fundamental aspects of proliferation with a strong ability to suppress early neoplasia in epithelial cells. We recently found that RUNX3 interacts with prominent oncogenic proteins to orchestrate anti-growth and cancer immunity programs. Detailing the interaction of RUNX3 with these proteins and the interplay between RUNX members will yield novel insights on how cancer initiates from stem cells and how malignancy is sustained. The fact that RUNX3 is frequently hypermethylated in cancer indicates that, unlike many tumour suppressors that are mutated in cancer, we may be able to re-activate the silenced RUNX3 to restrain aberrant proliferation and reverse tumour growth.

Research Fellow - Prof. Yoshiaki Ito's Lab
Cancer Science Institute of Singapore | Open until filled

Two postdoctoral positions are available immediately in Prof. Yoshiaki Ito’s lab. The successful candidates will undertake different aspects of the following on-going project. 1) Characterization of RUNX3 in stem cells and cancer development The RUNX family of developmental transcription factors, comprising RUNX1, 2 and 3, has been implicated in tumorigenesis. In particular, our work established RUNX3 as a regulator of fundamental aspects of proliferation with a strong ability to suppress early neoplasia in epithelial cells. We recently found that RUNX3 interacts with prominent oncogenic proteins to orchestrate anti-growth and cancer immunity programs. Detailing the interaction of RUNX3 with these proteins and the interplay between RUNX members will yield novel insights on how cancer initiates from stem cells and how malignancy is sustained. The fact that RUNX3 is frequently hypermethylated in cancer indicates that, unlike many tumour suppressors that are mutated in cancer, we may be able to re-activate the silenced RUNX3 to restrain aberrant proliferation and reverse tumour growth.